Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Q1-2022 Ophthalmology Update

Skip to the end of the Expertise Menu

Q1-2022 Ophthalmology Update

The eyecare sector continues to be one of the most active spaces within healthcare services driven by industry tailwinds and intense competition for deals. Q1 was an exceptionally active quarter with most closings taking place in January, likely due to delays at year end. The eased rhetoric around capital gains increases gave many owners comfort in closing their respective deals in CY 2022, contributing to an influx of deal activity in the first few weeks of the year.

With transaction volume hitting record levels in Q1, Provident expects a slight slow down in activity for add-on deals throughout the rest of the year as a few notable PE-backed platforms focus on sale processes of their own.

To print and download the full Ophthalmology Update report, please click below…

[holo_button icon=”/wp-content/uploads/2022/04/Q1-2022-Ophthalmology-Newsletter-vF.pdf” link=”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]


Sources: SEC Filings; Company Press Releases, and Reports; IBISWorld; Capital IQ; PHP Estimates and Research. This document has been compiled with publicly available information. Provident Healthcare Partners, LLC makes no guarantee of its accuracy or completeness. No data or statement should be construed to be a recommendation for the purchase, sale, or retention of any security.